|
DE3583799D1
(de)
*
|
1985-01-11 |
1991-09-19 |
Abbott Lab Ltd |
Feste zubereitung mit langsamer freisetzung.
|
|
WO1987004077A1
(en)
*
|
1986-01-03 |
1987-07-16 |
The University Of Melbourne |
Gastro-oesophageal reflux composition
|
|
CA1302659C
(en)
*
|
1986-10-24 |
1992-06-09 |
Hans-Peter K. Gribi |
Dental impression material
|
|
EP0275336A1
(de)
*
|
1987-01-20 |
1988-07-27 |
Knoll Ag |
Arzneimittelzubereitung mit protahierender Wirkung
|
|
US5064736A
(en)
*
|
1988-03-23 |
1991-11-12 |
Olin Corporation |
Electrostatic method for multicolor imaging from a single toner bath
|
|
DE4002281A1
(de)
*
|
1990-01-26 |
1991-08-01 |
Lohmann Therapie Syst Lts |
Transdermales therapeutisches system mit dem wirkstoff tulobuterol
|
|
NL9002008A
(nl)
|
1990-09-12 |
1992-04-01 |
Stichting Centr Diergeneeskund |
Recombinant dna en rna en daarvan afgeleide produkten.
|
|
FR2676364B1
(fr)
*
|
1991-05-17 |
1993-09-10 |
Lafon Labor |
Composition pharmaceutique a base de derives d'aminobutanone.
|
|
US5368862A
(en)
*
|
1991-12-18 |
1994-11-29 |
Merck & Co., Inc. |
Sustained release tablets containing alginate
|
|
US5411746A
(en)
*
|
1993-02-24 |
1995-05-02 |
Warner-Jenkinson Company, Inc. |
Dye compositions and methods for film coating tablets and the like
|
|
US5670169A
(en)
*
|
1993-12-20 |
1997-09-23 |
E.R. Squibb & Sons, Inc. |
Wound hydrating gel with novel preservative system and low cytotoxicity
|
|
US6692766B1
(en)
*
|
1994-06-15 |
2004-02-17 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Controlled release oral drug delivery system
|
|
DE4443358A1
(de)
*
|
1994-12-06 |
1996-06-13 |
Basf Ag |
Depot-Arzneimittel
|
|
US5879712A
(en)
*
|
1995-06-07 |
1999-03-09 |
Sri International |
Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
|
|
US5811126A
(en)
*
|
1995-10-02 |
1998-09-22 |
Euro-Celtique, S.A. |
Controlled release matrix for pharmaceuticals
|
|
US5705190A
(en)
*
|
1995-12-19 |
1998-01-06 |
Abbott Laboratories |
Controlled release formulation for poorly soluble basic drugs
|
|
WO1998056357A1
(en)
*
|
1995-12-19 |
1998-12-17 |
Abbott Laboratories |
A controlled release formulation for poorly soluble basic drugs
|
|
US6551616B1
(en)
*
|
1997-04-11 |
2003-04-22 |
Abbott Laboratories |
Extended release formulations of erythromycin derivatives
|
|
US20050064033A1
(en)
*
|
1997-04-11 |
2005-03-24 |
Notario Gerard F. |
Extended release formulations of erythromycin derivatives
|
|
US6010718A
(en)
|
1997-04-11 |
2000-01-04 |
Abbott Laboratories |
Extended release formulations of erythromycin derivatives
|
|
IN186245B
(de)
|
1997-09-19 |
2001-07-14 |
Ranbaxy Lab Ltd |
|
|
US7022683B1
(en)
*
|
1998-05-13 |
2006-04-04 |
Carrington Laboratories, Inc. |
Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
|
|
BG65116B1
(bg)
*
|
2000-01-06 |
2007-03-30 |
Abbott Laboratories |
Лекарствена форма с контролирано освобождаване наслабо разтворими основни лекарствени средства
|
|
US6565882B2
(en)
|
2000-02-24 |
2003-05-20 |
Advancis Pharmaceutical Corp |
Antibiotic composition with inhibitor
|
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
|
EP1313486A1
(de)
*
|
2000-02-29 |
2003-05-28 |
Teva Pharmaceutical Industries Ltd. |
Verfahren zur herstellung des clarithromycins und eines clarithromycin-zwischenprodukt; clarithromycin wesentlich frei von oxime; und pharmazeutische zusammensetzung die sie enthalten
|
|
US6541014B2
(en)
|
2000-10-13 |
2003-04-01 |
Advancis Pharmaceutical Corp. |
Antiviral product, use and formulation thereof
|
|
US20020068078A1
(en)
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
|
US7494669B2
(en)
*
|
2001-02-28 |
2009-02-24 |
Carrington Laboratories, Inc. |
Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
|
|
US6777000B2
(en)
*
|
2001-02-28 |
2004-08-17 |
Carrington Laboratories, Inc. |
In-situ gel formation of pectin
|
|
US6642276B2
(en)
*
|
2001-10-01 |
2003-11-04 |
M/S Ind-Swift Limited |
Controlled release macrolide pharmaceutical formulations
|
|
WO2003037304A1
(en)
*
|
2001-11-02 |
2003-05-08 |
Wockhardt Limited |
Controlled release compositions for macrolide antimicrobial agents
|
|
US6602911B2
(en)
|
2001-11-05 |
2003-08-05 |
Cypress Bioscience, Inc. |
Methods of treating fibromyalgia
|
|
AU2003245504A1
(en)
*
|
2002-06-14 |
2003-12-31 |
Andrx Corporation |
Pharmaceutical compositions for drugs having ph-dependentsolubility
|
|
SI21300A
(sl)
*
|
2002-10-08 |
2004-04-30 |
Krka, Tovarna Zdravil, D.D., Novo Mesto |
Farmacevtske formulacije z alginati
|
|
US20100092562A1
(en)
*
|
2002-11-26 |
2010-04-15 |
Hollenbeck R Gary |
Sustained-release drug delivery compositions and methods
|
|
GB0230034D0
(en)
*
|
2002-12-23 |
2003-01-29 |
Biochemie Gmbh |
Organic compounds
|
|
US7063862B2
(en)
*
|
2003-06-03 |
2006-06-20 |
Biokey, Inc. |
Pharmaceutical composition and method for treating
|
|
AU2004249211A1
(en)
*
|
2003-06-16 |
2004-12-29 |
Andrx Pharmaceuticals, Llc |
Oral extended-release composition
|
|
US20050053658A1
(en)
*
|
2003-09-09 |
2005-03-10 |
Venkatesh Gopi M. |
Extended release systems for macrolide antibiotics
|
|
WO2005009365A2
(en)
|
2003-07-21 |
2005-02-03 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
|
WO2005009364A2
(en)
|
2003-07-21 |
2005-02-03 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
|
CA2533292C
(en)
|
2003-07-21 |
2013-12-31 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
|
EP1653925A1
(de)
|
2003-08-11 |
2006-05-10 |
Advancis Pharmaceutical Corporation |
Robustes pellet
|
|
EP1653924A4
(de)
|
2003-08-12 |
2009-09-09 |
Middlebrook Pharmaceuticals In |
Antibiotisches produkt, seine verwendung und formulierung
|
|
AU2004270170B2
(en)
|
2003-08-29 |
2011-01-27 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
|
AU2004273830B2
(en)
|
2003-09-15 |
2011-03-24 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
|
US20050084540A1
(en)
*
|
2003-10-17 |
2005-04-21 |
Indranil Nandi |
Taste masking antibiotic composition
|
|
US8168228B2
(en)
*
|
2003-10-17 |
2012-05-01 |
Sandoz Ag |
Antibiotic clarithromycin micropellet compositions
|
|
US20050101547A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Sadatrezaei Mohsen |
Stabilized azithromycin composition
|
|
US7943585B2
(en)
|
2003-12-22 |
2011-05-17 |
Sandoz, Inc. |
Extended release antibiotic composition
|
|
CA2554771A1
(en)
|
2004-01-30 |
2005-08-18 |
Johns Hopkins University |
Nitroxyl progenitor compounds and methods of use
|
|
US20050260263A1
(en)
*
|
2004-05-18 |
2005-11-24 |
Panion & Bf Biotech Inc. |
Sustained release formulation for sparingly soluble main drugs
|
|
US8980930B2
(en)
|
2004-06-25 |
2015-03-17 |
The Johns Hopkins University |
Angiogenesis inhibitors
|
|
JP2008505124A
(ja)
|
2004-07-02 |
2008-02-21 |
アドバンシス ファーマスーティカル コーポレイション |
パルス送達用錠剤
|
|
US20070020333A1
(en)
*
|
2005-07-20 |
2007-01-25 |
Chin-Chih Chiang |
Controlled release of hypnotic agents
|
|
JP2009502961A
(ja)
|
2005-07-29 |
2009-01-29 |
コンサート ファーマシューティカルズ インコーポレイテッド |
新規な医薬組成物
|
|
US8912214B2
(en)
*
|
2005-07-29 |
2014-12-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of Chk2 kinase inhibitors for cancer treatment
|
|
US7994220B2
(en)
*
|
2005-09-28 |
2011-08-09 |
Cypress Bioscience, Inc. |
Milnacipran for the long-term treatment of fibromyalgia syndrome
|
|
US20070128272A1
(en)
*
|
2005-12-07 |
2007-06-07 |
Zerbe Horst G |
Multi-vitamin and mineral supplement
|
|
US8778924B2
(en)
|
2006-12-04 |
2014-07-15 |
Shionogi Inc. |
Modified release amoxicillin products
|
|
US8357394B2
(en)
|
2005-12-08 |
2013-01-22 |
Shionogi Inc. |
Compositions and methods for improved efficacy of penicillin-type antibiotics
|
|
NZ609381A
(en)
|
2006-03-17 |
2014-10-31 |
Cardioxyl Pharmaceuticals Inc |
N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
|
|
US8299052B2
(en)
*
|
2006-05-05 |
2012-10-30 |
Shionogi Inc. |
Pharmaceutical compositions and methods for improved bacterial eradication
|
|
WO2008088881A1
(en)
|
2007-01-19 |
2008-07-24 |
Xcovery, Inc. |
Kinase inhibitor compounds
|
|
BRPI0817562A2
(pt)
|
2007-09-26 |
2017-05-02 |
Cardioxyl Pharmaceuticals Inc |
derivados de n-hidroxilsulfonamida como novos doadores de niltroxil fisiologicamente úteis
|
|
JP5416716B2
(ja)
*
|
2007-12-28 |
2014-02-12 |
アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ |
グリコーゲンおよびアルギン酸塩の会合体に基づく徐放性製剤
|
|
PL2278975T3
(pl)
|
2008-05-07 |
2017-02-28 |
Cardioxyl Pharmaceuticals Inc. |
Nowe związki nitrozowe jako donory nitroksylu i metody ich zastosowania
|
|
CA2728408C
(en)
|
2008-06-19 |
2017-12-05 |
Congxin Liang |
Substituted pyridazine carboxamide compounds as kinase inhibitor compounds
|
|
EP2350012B1
(de)
|
2008-10-06 |
2017-06-28 |
The Johns Hopkins University |
Chinolinverbindungen als angiogenese-, humane methioninaminopeptidase- und sirt1-hemmer sowie verfahren zur behandlung von erkrankungen
|
|
US20110160200A1
(en)
*
|
2009-11-23 |
2011-06-30 |
Cardioxyl Pharmaceuticals, Inc. |
Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
|
|
JP5860811B2
(ja)
|
2009-12-03 |
2016-02-16 |
オプコ ヘルス インコーポレイテッド |
高硫酸化二糖製剤
|
|
CN102753520B
(zh)
|
2009-12-07 |
2016-06-08 |
约翰斯霍普金斯大学 |
N-酰氧基磺酰胺和n-羟基-n-酰基磺酰胺衍生物
|
|
CA2782248A1
(en)
|
2009-12-07 |
2011-06-16 |
Cardioxyl Pharmaceuticals, Inc. |
Bis-acylated hydroxylamine derivatives
|
|
US20120082719A1
(en)
*
|
2010-10-05 |
2012-04-05 |
Sam Poon Ang |
Compositions For Treating Chronic Viral Infections
|
|
US20120082720A1
(en)
*
|
2010-10-05 |
2012-04-05 |
Sam Poon Ang |
Compositions For Treating Chronic Viral Infections
|
|
KR101886812B1
(ko)
|
2010-10-08 |
2018-08-08 |
엑스커버리 홀딩스, 인코포레이티드 |
치환된 피리다진 카복사미드 화합물
|
|
SG11201401587QA
(en)
|
2011-10-17 |
2014-07-30 |
Univ Johns Hopkins |
Meldrum 's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors
|
|
JP6306602B2
(ja)
|
2012-11-01 |
2018-04-04 |
ザ ジョンズ ホプキンス ユニバーシティ |
分子内環化−脱離による制御されたｈｎｏ放出
|
|
ES2705240T3
(es)
|
2013-01-18 |
2019-03-22 |
Cardioxyl Pharmaceuticals Inc |
Composiciones farmacéuticas que comprenden donadores de nitroxilo
|
|
CN118557711A
(zh)
|
2013-04-07 |
2024-08-30 |
博德研究所 |
用于个性化瘤形成疫苗的组合物和方法
|
|
US10801070B2
(en)
|
2013-11-25 |
2020-10-13 |
The Broad Institute, Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer
|
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
|
KR20160101073A
(ko)
|
2013-12-20 |
2016-08-24 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신생항원 백신과의 병용 요법
|
|
ES2734060T3
(es)
|
2014-01-17 |
2019-12-04 |
Cardioxyl Pharmaceuticals Inc |
Donadores de nitroxilo de N-hidroximetanosulfonamida
|
|
ES2749682T3
(es)
|
2014-05-27 |
2020-03-23 |
Cardioxyl Pharmaceuticals Inc |
Derivados de pirazolona como donadores de nitroxilo
|
|
WO2015183838A1
(en)
|
2014-05-27 |
2015-12-03 |
The Johns Hopkins University |
N-hydroxylamino-barbituric acid derivatives as nitroxyl donors
|
|
US9464061B2
(en)
|
2014-05-27 |
2016-10-11 |
The Johns Hopkins University |
N-hydroxylamino-barbituric acid derivatives
|
|
EP3757211A1
(de)
|
2014-12-19 |
2020-12-30 |
The Broad Institute, Inc. |
Verfahren zur profilierung des t-zell-rezeptor-repertoirs
|
|
EP3234193B1
(de)
|
2014-12-19 |
2020-07-15 |
Massachusetts Institute of Technology |
Molekulare biomarker für krebsimmuntherapie
|
|
RU2017126462A
(ru)
|
2014-12-23 |
2019-01-24 |
Церекор, Инк. |
Соединения, композиции и способы
|
|
RU2733754C2
(ru)
|
2015-05-20 |
2020-10-06 |
Те Брод Инститьют Инк. |
Общие неоантигены
|
|
ES2903212T3
(es)
|
2015-06-09 |
2022-03-31 |
Ocuphire Pharma Inc |
Usos y procedimientos de preparación de fluorociclopentenilcitosina
|
|
KR101592144B1
(ko)
|
2015-06-19 |
2016-02-04 |
고려대학교 산학협력단 |
요오드 캡슐, 이의 제조방법 및 이를 포함하는 소금
|
|
US10383825B2
(en)
|
2015-08-13 |
2019-08-20 |
Temple University—Of the Commonwealth System of Higher Education |
Calcium alginate dosage formulations, and methods of making and using thereof
|
|
MX2018002193A
(es)
|
2015-09-04 |
2018-08-01 |
Rexahn Pharmaceuticals Inc |
Metodo de uso de quinoxalinilo-piperazinamida.
|
|
US20190346442A1
(en)
|
2016-04-18 |
2019-11-14 |
The Broad Institute, Inc. |
Improved hla epitope prediction
|
|
RS62695B1
(sr)
|
2016-10-03 |
2022-01-31 |
Highlightll Pharmaceutical Hainan Co Ltd |
Novi jak1 selektivni inhibitori i njihove upotrebe
|
|
US11549149B2
(en)
|
2017-01-24 |
2023-01-10 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
|
BR112020022294A2
(pt)
|
2018-05-04 |
2021-02-23 |
Tollys |
composição e uso de uma composição
|
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
EP3955923A1
(de)
|
2019-04-18 |
2022-02-23 |
The Regents Of The University Of Michigan |
Kombination mit checkpoint-inhibitoren zur behandlung von krebs
|
|
JP2023528805A
(ja)
|
2020-05-26 |
2023-07-06 |
ディオニス セラピューティクス インコーポレイテッド |
核酸人工ミニプロテオームライブラリー
|
|
JP2023528479A
(ja)
|
2020-06-05 |
2023-07-04 |
ヘンリー フォード ヘルス システム |
肺がん及び前立腺がんの治療に使用するダクラタスビル
|
|
US20240239764A1
(en)
|
2020-12-22 |
2024-07-18 |
Mekanistic Therapeutics |
Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors
|
|
WO2022189861A1
(en)
|
2021-03-08 |
2022-09-15 |
Tollys |
Carbohydrate conjugates of tlr3 ligands and uses thereof
|
|
WO2023016321A1
(zh)
|
2021-08-10 |
2023-02-16 |
贝达药业股份有限公司 |
恩沙替尼或其盐在治疗携带met 14外显子跳跃突变的疾病中的用途
|
|
WO2023076733A1
(en)
|
2021-11-01 |
2023-05-04 |
Dana-Farber Cancer Institute, Inc. |
Biologically selected nucleic acid artificial mini-proteome libraries
|